Baseline characteristics of the patients with PCI or conservative treatment
| All patients total | Total | PCI | Conservative | P value |
| Number of patients | 5770 (100%) | 3868 (67.0) | 1902 (33.0) | |
| Age, years, (median, IQR) | 83 (81–85) | 83 (81–85) | 83 (81–85) | <0.001* |
| Female | 2568 (44.5) | 1655 (64.5) | 913 (35.5) | <0.001‡ |
| Male | 3202 (55.5) | 2213 (69.1) | 989 (30.9) | |
| BMI (mean, SD) | 26.0 (4.7) | 26.0 (5.1) | 25.8 (4.0) | 0.266† |
| Hb (mean, SD) | 132.1 (16.0) | 133.5 (15.3) | 132.1 (16.0) | <0.01† |
| CRP, median (IQR) | 5 (2.3–12) | 5 (2–10.5) | 5 (2.8–13) | <0.01* |
| LDL (mean, SD) | 2.8 (1.1) | 2.4 (1.1) | 2.8 (1.1) | <0.001* |
| eGFR (mL/min/1.73 m2) | 0.75‡ | |||
| >60 | 3123 (54.1) | 2077 (66.5) | 1046 (33.5) | |
| 60–30 | 2071 (35.8) | 1397 (67.5) | 674 (32.5) | |
| 30–15 | 260 (4.5) | 172 (66.2) | 88 (33.9) | |
| Prior MI | 2046 (35.5) | 1368 (35.4) | 678 (35.7) | 0.805‡ |
| Heart failure | 686 (12.0) | 429 (11.7) | 257 (14.3) | <0.01‡ |
| Prior stroke | 605 (10.5) | 394 (10.2) | 211 (11.2) | 0.28‡ |
| Prior revascularisation: PCI | 1051 (18.2) | 759 (19.6) | 292 (15.4) | <0.001‡ |
| CABG | 309 (5.3) | 28 (0.7) | 281 (14.8) | <0.001‡ |
| Hypertension | 3604 (62.5) | 2387 (61.7) | 1217 (64.0) | 0.19‡ |
| Diabetes | 1363 (23.6) | 888 (23.0) | 475 (25.0) | 0.09‡ |
| LVEF | <0.126 | |||
| ≥50% | 2533 (43.9) | 1717 (67.8) | 816 (32.2) | |
| 40%–50% | 976 (17.0) | 668 (68.4) | 308 (31.6) | |
| 30%–39% | 656 (11.4) | 419 (63.9) | 237 (36.1) | |
| <30% | 285 (4.9) | 178 (62.5) | 107 (37.5) | |
| Unknown | 51 (1.0) | 30 (66.7) | 15 (33.3) | |
| Medications | ||||
| Aspirin | 5224 (90.5) | 3600 (93.3) | 1624 (85.5) | <0.001‡ |
| P2Y12 inhibitors | 4772 (82.7) | 3654 (94.7) | 1118 (58.8) | <0.001‡ |
| Betablockers | 4964 (86.0) | 3344 (86.7) | 1620 (85.3) | 0.14‡ |
| ACEi/ARB | 3160 (54.8) | 2197 (56.9) | 963 (50.7) | <0.001‡ |
| Statin | 4958 (85.9) | 3426 (88.6) | 1532 (80.6) | <0.001‡ |
| Antikoagulantia | 805 (13.9) | 476 (12.3) | 329 (17.3) | <0.001‡ |
Treatment data available for 5770 patients, median follow-up time: 2.6 years (min=0, max=5.2).
Data are number of patients and percentages, unless otherwise noted.
*Mann-Whitney test.
†T-test.
‡χ2 test.
ACEi, ACE inhibitor; ARB, angiotensin II receptor antagonists; BMI, body mass index; BMS, bare metal stent; CABG, coronary artery bypass graft; CRP, C reactive protein; DES, drug eluting stent; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.